Abstract

Purpose: To collect information on unintended drug exposure during pregnancy in early clinical drug development.
Materials and methods: Questionnaire mailed in autumn 2015 to members of human pharmacology societies in Europe for anonymous responses via the online tool SurveyMonkey.
Results: 53 of the ~ 700 addressees participated in the survey. 23 female trial participants and 11 female partners of male trial participants were exposed to investigational medicinal products during unintended pregnancies in a clinical trial. Most survey respondents confirmed adequate contraceptive methods by in/exclusion criteria and the use of pregnancy tests in female trial participants at screening and before the first dose. The last menstrual period was documented less frequently (at screening: 28 of 44, before first dose: 5 of 44 respondents). A considerable proportion of respondents denied the routine use of compliance checks about the appropriate use of contraceptive methods, had no procedures in place if contraceptive methods failed, and did not train physicians in instructing trial participants about the appropriate use of contraceptive methods.
Conclusion: The methods to avoid unintended pregnancies during participation in a clinical trial need improvement and should include (i) pregnancy tests, (ii) documentation of last menstrual period before the first dose, (iii) compliance checks of the appropriate use of contraceptive methods, and (iv) training of trial physicians. Procedures should be in place for what to do if contraceptive methods fail.

Author Details

Authors

• Katharina Erb-Zohar
• Hildegard Sourgens
• Kerstin Breithaupt-Groegler
• Christine Klipping

Departments

• Association for Applied Human Pharmacology (AGAH e.V.), Hamburg, Germany

Address


Dr. Katharina Erb-Zohar

clinphase
Pfarrgalle 22, 63679 Schotten, Germany
Email: [email protected]

Log in for Subscribers

Citation